MyFinsight
Home
Blog
About
Proceeds from issuance of
common stock under...
$99K
(-48.17%↓ Y/Y)
Net cash provided by
(used in) financing...
$99K
(124.21%↑ Y/Y)
Net increase
(decrease) in cash, cash...
-$27,901K
(-200.17%↓ Y/Y)
Canceled cashflow
$99K
Stock-based compensation
$2,357K
(-64.75%↓ Y/Y)
Accounts payable
$843K
(585.37%↑ Y/Y)
Depreciation expense
$699K
(-49.20%↓ Y/Y)
Prepaid expenses and
other assets
-$483K
(-198.77%↓ Y/Y)
Non-cash interest
expense related to note...
$125K
(-44.20%↓ Y/Y)
Loss on disposal of
property and equipment
-$99K
Right-of-use assets and lease
liabilities, net
$9K
(-99.62%↓ Y/Y)
Proceeds from sale of
property and equipment
$28K
Net cash used in
operating activities
-$27,535K
(61.14%↑ Y/Y)
Net cash (used in)
provided by investing...
-$465K
(-100.75%↓ Y/Y)
Canceled cashflow
$4,615K
Canceled cashflow
$28K
Net loss
-$30,359K
(57.29%↑ Y/Y)
Purchases of property and
equipment
$493K
(-82.46%↓ Y/Y)
Deferred revenue
-$1,051K
(79.97%↑ Y/Y)
Accrued expense and
other liabilities
-$740K
(73.00%↑ Y/Y)
Back
Back
Cash Flow
TScan Therapeutics, Inc. (TCRX)
TScan Therapeutics, Inc. (TCRX)
source: myfinsight.com